Literature DB >> 30131448

p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT.

Yang Yang-Hartwich1, Roslyn Tedja1, Cai M Roberts2, Jamie Goodner-Bingham1, Carlos Cardenas1, Marta Gurea1, Natalia J Sumi1, Ayesha B Alvero1, Carlotta A Glackin2, Gil Mor3.   

Abstract

Epithelial-mesenchymal transition (EMT) is a critical process involved in cancer metastasis and chemoresistance. Twist1 is a key EMT-inducing transcription factor, which is upregulated in multiple types of cancers and has been shown to promote tumor cell invasiveness and support tumor progression. Conversely, p53 is a tumor suppressor gene that is frequently mutated in cancers. This study demonstrates the ability of wild-type (WT) p53 to promote the degradation of Twist1 protein. By forming a complex with Twist1 and the E3 ligase Pirh2, WT p53 promotes the ubiquitination and proteasomal degradation of Twist1, thus inhibiting EMT and maintaining the epithelial phenotype. The ability of p53 to induce Twist1 degradation is abrogated when p53 is mutated. Consequently, the loss of p53-induced Twist1 degradation leads to EMT and the acquisition of a more invasive cancer phenotype.Implication: These data provide new insight into the metastatic process at the molecular level and suggest a signaling pathway that can potentially be used to develop new prognostic markers and therapeutic targets to curtail cancer progression. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30131448      PMCID: PMC6800184          DOI: 10.1158/1541-7786.MCR-18-0238

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  74 in total

1.  Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells.

Authors:  Ayesha B Alvero; Michele K Montagna; Jennie C Holmberg; Vinicius Craveiro; David Brown; Gil Mor
Journal:  Mol Cancer Ther       Date:  2011-06-15       Impact factor: 6.261

2.  Topors acts as a SUMO-1 E3 ligase for p53 in vitro and in vivo.

Authors:  Stefan Weger; Eva Hammer; Regine Heilbronn
Journal:  FEBS Lett       Date:  2005-09-12       Impact factor: 4.124

3.  Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells.

Authors:  Ayesha B Alvero; David O'Malley; David Brown; Graham Kelly; Manish Garg; Wei Chen; Thomas Rutherford; Gil Mor
Journal:  Cancer       Date:  2006-02-01       Impact factor: 6.860

4.  The epithelial-mesenchymal transition generates cells with properties of stem cells.

Authors:  Sendurai A Mani; Wenjun Guo; Mai-Jing Liao; Elinor Ng Eaton; Ayyakkannu Ayyanan; Alicia Y Zhou; Mary Brooks; Ferenc Reinhard; Cheng Cheng Zhang; Michail Shipitsin; Lauren L Campbell; Kornelia Polyak; Cathrin Brisken; Jing Yang; Robert A Weinberg
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

5.  Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial.

Authors:  Douglas Altman; Guillermo Carroli; Lelia Duley; Barbara Farrell; Jack Moodley; James Neilson; David Smith
Journal:  Lancet       Date:  2002-06-01       Impact factor: 79.321

6.  Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer.

Authors:  Ian R Logan; Luke Gaughan; Stuart R C McCracken; Vasileia Sapountzi; Hing Y Leung; Craig N Robson
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

7.  TP53 mutation, epithelial-mesenchymal transition, and stemlike features in breast cancer subtypes.

Authors:  Danila Coradini; Marco Fornili; Federico Ambrogi; Patrizia Boracchi; Elia Biganzoli
Journal:  J Biomed Biotechnol       Date:  2012-07-30

8.  The proto-oncogene TWIST1 is regulated by microRNAs.

Authors:  Maarja-Liisa Nairismägi; Annette Füchtbauer; Rodrigo Labouriau; Jesper Bertram Bramsen; Ernst-Martin Füchtbauer
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

9.  Role of Pirh2 in mediating the regulation of p53 and c-Myc.

Authors:  Anne Hakem; Miyuki Bohgaki; Bénédicte Lemmers; Elisabeth Tai; Leonardo Salmena; Elzbieta Matysiak-Zablocki; Yong-Sam Jung; Jana Karaskova; Lilia Kaustov; Shili Duan; Jason Madore; Paul Boutros; Yi Sheng; Marta Chesi; P Leif Bergsagel; Bayardo Perez-Ordonez; Anne-Marie Mes-Masson; Linda Penn; Jeremy Squire; Xinbin Chen; Igor Jurisica; Cheryl Arrowsmith; Otto Sanchez; Samuel Benchimol; Razqallah Hakem
Journal:  PLoS Genet       Date:  2011-11-17       Impact factor: 5.917

10.  TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.

Authors:  Cai M Roberts; Michelle A Tran; Mary C Pitruzzello; Wei Wen; Joana Loeza; Thanh H Dellinger; Gil Mor; Carlotta A Glackin
Journal:  Sci Rep       Date:  2016-11-23       Impact factor: 4.379

View more
  19 in total

1.  ZNF451 stabilizes TWIST2 through SUMOylation and promotes epithelial-mesenchymal transition.

Authors:  Wang Zeng; Shuchen Gu; Yi Yu; Yili Feng; Mu Xiao; Xin-Hua Feng
Journal:  Am J Cancer Res       Date:  2021-03-01       Impact factor: 6.166

Review 2.  Vascular mimicry: Triggers, molecular interactions and in vivo models.

Authors:  Stephen L Wechman; Luni Emdad; Devanand Sarkar; Swadesh K Das; Paul B Fisher
Journal:  Adv Cancer Res       Date:  2020-07-16       Impact factor: 6.242

Review 3.  The Role of E3 Ligase Pirh2 in Disease.

Authors:  Alexandra Daks; Olga Fedorova; Sergey Parfenyev; Ivan Nevzorov; Oleg Shuvalov; Nickolai A Barlev
Journal:  Cells       Date:  2022-04-30       Impact factor: 7.666

Review 4.  Opposing Roles of Wild-type and Mutant p53 in the Process of Epithelial to Mesenchymal Transition.

Authors:  Oleg Semenov; Alexandra Daks; Olga Fedorova; Oleg Shuvalov; Nickolai A Barlev
Journal:  Front Mol Biosci       Date:  2022-06-23

Review 5.  Twist1: A Double-Edged Sword in Kidney Diseases.

Authors:  Jiafa Ren; Steven D Crowley
Journal:  Kidney Dis (Basel)       Date:  2020-01-17

6.  MicroRNA profiling of diabetic atherosclerosis in a rat model.

Authors:  Yuejin Li; Le Xiao; Jinyuan Li; Ping Sun; Lei Shang; Jian Zhang; Quan Zhao; Yiming Ouyang; Linhai Li; Kunmei Gong
Journal:  Eur J Med Res       Date:  2018-11-03       Impact factor: 2.175

7.  The RNA-binding protein HuR is a novel target of Pirh2 E3 ubiquitin ligase.

Authors:  Alexandra Daks; Alexey Petukhov; Olga Fedorova; Oleg Shuvalov; Alena Kizenko; Elizaveta Tananykina; Elena Vasileva; Oleg Semenov; Andrew Bottrill; Nickolai Barlev
Journal:  Cell Death Dis       Date:  2021-06-05       Impact factor: 8.469

8.  miR-138-5p induces aggressive traits by targeting Trp53 expression in murine melanoma cells, and correlates with poor prognosis of melanoma patients.

Authors:  Adriana Taveira da Cruz; Aline Hunger; Fabiana Henriques Machado de Melo; Ana Carolina Monteiro; Geneviève Catherine Paré; Dulce Lai; Débora Kristina Alves-Fernandes; Ana Luisa Pedroso Ayub; Esteban Mauricio Cordero; José Franco da Silveira Filho; Regine Schneider-Stock; Bryan Eric Strauss; Victor Tron; Miriam Galvonas Jasiulionis
Journal:  Neoplasia       Date:  2021-07-08       Impact factor: 5.715

9.  Mutant p53 and Twist1 Co-Expression Predicts Poor Prognosis and Is an Independent Prognostic Factor in Breast Cancer.

Authors:  Yong-Qu Zhang; Fan Zhang; Yun-Zhu Zeng; Min Chen; Wen-He Huang; Jun-Dong Wu; Wei-Ling Chen; Wen-Liang Gao; Jing-Wen Bai; Rui-Qin Yang; Huan-Cheng Zeng; Xiao-Long Wei; Guo-Jun Zhang
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

10.  The Deubiquitinase USP4 Stabilizes Twist1 Protein to Promote Lung Cancer Cell Stemness.

Authors:  Fengtian Li; Qingyong Hu; Tao He; Jing Xu; Yong Yi; Siyi Xie; Liangping Ding; Mengyuan Fu; Rongtian Guo; Zhi-Xiong Jim Xiao; Mengmeng Niu
Journal:  Cancers (Basel)       Date:  2020-06-15       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.